Thyroid Cancers | Clinical

June 25, 2022

Vivek Subbiah, MD, discusses the adverse events that come with the use of kinase inhibitors to treat patients with thyroid cancer.

June 15, 2022

Nathan Pennell, MD, PhD, discusses a first-in-human trial of a novel RET inhibitor for patients with non–small cell lung cancer and medullary thyroid cancer.

June 03, 2022

Lori J. Wirth, MD, discusses the treatment options now available for patients with iodine-refractory differentiated thyroid cancer.

May 30, 2022

During a Targeted Oncology case-based roundtable event, Krzysztof J. Misiukiewicz, MD, discussed deciding to use NTRK inhibitor for the treatment of a 67-year-old woman with thyroid cancer.

May 20, 2022

Continuing to monitor trends will be important in regard to the American Thyroid Association developing other updates to its thyroid cancer treatment guidelines and trends.

May 13, 2022

In this companion article, David S. Hong, MD, considers the safety and efficacy of the first-generation TRK inhibitor larotrectinib and discusses how acquired resistance may affect research into second-generation agents.

May 12, 2022

Lori Wirth, MD, discusses her experience with NTRK-targeted therapies for patients with thyroid cancer.

May 06, 2022

Increased risks of several solid tumors found to be associated with radioactive iodine treatment for patients with childhood and young-adulthood differentiated thyroid cancer.

April 28, 2022

Yuliya Mikheeva, MD, PhD, discusses the design of the phase 2 ANAPLAST-NEO study

April 26, 2022

In the second interview of the series, Marcia Brose, MD, PhD, reviews currently available therapies for NTRK fusion-positive thyroid cancer and highlights clinical factors affecting treatment decision-making.